Aug 28, 2012

Farmak JSC begins marketing Sinarta, a drug to treat osteoarthritis

Farmak JSC has expanded the range of chondroprotectors by launching Sinarta, a glucosamine sulfate drug that comes as a solution for injection. This medication has augmented the portfolio of drugs which rheumatologists, traumatologists, and neurologists may use to treat inflammatory and degenerative diseases of the musculoskeletal system.

Sinarta is the first generic glucosamine sulfate injection drug in Ukraine. It comes as a solution for intramuscular administration.

Sinarta is produced in the form of solution for injection: 5 ampoules with active substance and 5 ampoules with solvent per package.

Back to the News

Previous Next

More news

Farmak’s International Office acquires Polish Symphar

As of 27 March 2024, Farmak’s International Office has successfully finalized its acquisition of Symphar, becoming the sole owner of the Polish pharmaceutical company. The acquisition represents a part of Farmak’s international expansion strategy “Farmak 2.0: From local to global success”. This M&A is an important next step after last year’s ...

Mar 28, 2024

Farmak presented its medicines at one of the largest ra...

At the beginning of March, the European Congress of Radiology (ECR) was held in Vienna, Austria. The leader of the Ukrainian pharmaceutical market*, Farmak presented at ECR contrast drugs used during magnetic resonance imaging. ECR is one of the largest medical events in Europe and the second largest radiology conference in the world. More than […]

Mar 14, 2024

Farmak employees donated more than 10 liters of blood

The pharmaceutical company Farmak took part in a two-day blood donation marathon organized by the Ministry of Justice of Ukraine. In total, the campaign managed to collect more than 315 liters of blood, more than 10 of which were donated by Farmak employees. The blood donation marathon was held jointly with the Kyiv Central Interregional […]

Feb 08, 2024